Paris, France, April 5, 2023 (Accesswire) -- Abivax SA, a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, today announces the appointment of Marc de Garidel as Chief Executive Officer (CEO) and Interim Board Chair, effective May 5, 2023.
Read full article here.
San Diego, CA, April 3, 2024 (Reuters) -- Alterome Therapeutics announced that it has successfully secured $132 million. Spearheaded by Goldman Sachs Alternatives, this a series B financing brings f
Henderson, NV, April 8, 2024 (Zura Bio) -- Zura Bio, a company focused on advancing treatments for autoimmune and inflammatory conditions, has named Robert Lisicki as its new Chief Executive Officer
Cambridge, MA, April 3, 2024 (Business Wire) -- Obsidian Therapeutics, Inc., a cutting-edge clinical-stage biotechnology company specializing in engineered cell and gene therapies, recently conclude
